Paris, 29 October 2012 – Nanobiotix, a French pioneer in nanomedicine that has developed NanoXray, a revolutionary therapeutic approach for the local treatment of cancer, today celebrated its successful listing on Segment C of NYSE Euronext in Paris.
NYSE Euronext welcomes Nanobiotix to its European market
The company was cofounded in 2003 by Laurent Lévy upon completion of his thesis on nanosemiconductors in the United States. Nanobiotix has since developed a totally new nanoparticles-based approach to the local treatment of cancer, called NanoXray. These nanoparticles enhance the radiotherapy efficacy within the tumour without increasing X-ray induced damage to surrounding healthy tissue. With its 30 Paris-based employees, Nanobiotix has started expanding its footprint internationally, signing its first development partnership in August 2012 with an Asian pharmaceutical company.
Nanobiotix (ticker code: NANO) was listed through the admission to trading of 8,053,880 existing shares and 2,361,607 new shares issued under a Global Offering, with full exercise of the extension clause and the over-allotment option. The Global Offering raised a total of approximately €14.2 million.
The admission and issue price of Nanobiotix shares was set at €6 per share, near the high end of the indicative spread. Market capitalisation stood at around €62.4 million on the day of listing.
“Our European market extends a warm welcome to Nanobiotix, and we are very pleased to be a source of financing for a growth company that challenges the conventional approaches to the treatment of cancer”, said Marc Lefèvre, Head of European Business Development and Client Coverage at NYSE Euronext. “NYSE Euronext in Paris has become the most important market for biotech and medical technology companies in Europe, with 18 transactions and around €430 million raised in the past three years.”
Laurent Lévy, CEO of Nanobiotix, added, “I was delighted by the success of our listing on NYSE Euronext’s regulated market, which gives us a fundamental advantage in terms of visibility. Nanobiotix will now be able to use its enhanced prestige to strengthen its communication strategy, a must if its NanoXray technology is to make inroads into the principal oncology markets.The listing of Nanobiotix on NYSE Euronext is an important step in the development of our company, and I would like to give heartfelt thanks to our partners, new shareholders and employees, who have all contributed to this success. After nearly a decade of research and development efforts we are now more focused than ever on the future and on the revolution taking place in the local treatment of cancer.
To mark its listing, Mr Lévy rang the opening bell of NYSE Euronext’s European market, in the presence of Nanobiotix’s senior managers and employees, its financial and legal partners and the listing team of NYSE Euronext.
NYSE Euronext – Press Relations
Caroline Tourrier: +33 (0)1 49 27 10 82
Louis-Victor Delouvrier / Emmanuel Huynh: +33 (0)1 44 71 98 53
Annie-Florence Loyer / Nadège Le Lezec: +33 (0)1 53 63 27 27
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca — represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of Europe’s leading derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers a comprehensive range of technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is included in the S&P 500 index. For more information, visit: http://www.nyx.com.
Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary method for the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action: nanoparticles interact with X-rays and maximize the effect of radiotherapy within tumour cells. NanoXray products enhance the radiotherapy efficacy in the tumour without increasing healthy tissue exposure to X-rays. NanoXray products can be used with all standard radiation equipment available in almost every hospital worldwide.
Founded in 2003, Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo and was initially funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. Nanobiotix’s objective is to become the leader in nanomedicine by establishing a strong presence in the principal oncology markets. With its NanoXray products Nanobiotix targets the major cancer indications (breast cancer, prostate cancer, lung cancer, etc.) in a potential market estimated at several billion dollars. Thanks to the purely physical mechanism of its nanoparticles, Nanobiotix operates a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market. To learn more about Nanobiotix, please visit us at: www.nanobiotix.com/fr.
The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.